Children’s Hospital Colorado 1st in the World to Implant Recently FDA-Approved Stent for Treatment of Congenital Heart Disease

Children’s Hospital Colorado (Children’s Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two.

The stent was developed by interventional cardiologist, Gareth Morgan, MD, who oversees the Interventional Congenital Cardiology program at Children’s Hospital Colorado in conjunction with NuMed for Children.

Unlike many other stents, the G-Armor is hand-manufactured with considerable capacity for expansion and minimal shortening during implantation. The result is a stent that can be dilated to accommodate a patient’s natural growth, potentially reducing the need for additional stent implantation – a key benefit to growing pediatric patients. The high expansion range also provides cardiac interventionalists the ability to treat a broader range of patients.

“I am proud to have led the development of the first custom stent approved by the FDA in a decade to treat congenital heart disease,” says Morgan, who is also an associate professor at the University of Colorado School of Medicine. “This new stent, in combination with our unmatched imaging technologies, removes significant surgical uncertainties, and is expected to result in improved outcomes for patients of all ages.”

The first patient was Randy Welch, who was told as a child that the small hole in his heart would close. But as a new dad working at the National Institutes of Health in Maryland, Welch learned the hole had expanded significantly and was causing his heart to pump extremely hard, which could ultimately result in heart failure. After moving back to Colorado and seeking cardiology care, Welch was quickly referred to Joseph Kay, MD, program director for the Children’s Colorado / UCHealth Adult Congenital Heart Disease program. This unique program on the Anschutz Medical Campus specializes in treating adults, like Welch, who were born with congenital heart defects.

Welch’s two options were either open heart surgery or implanting this new stent in the Children’s Colorado heart catheterization lab. With a second child on the way, Welch wanted the procedure with the lowest risk and quickest recovery time. Working with his colleague Jenny Zablah, MD, who leads the innovative interventional imaging team, Dr. Morgan created a 3D model of Welch’s heart and determined that Welch was a good candidate for the new stent.

Like many young adults with congenital heart disease, Dr. Kay and Dr. Morgan deemed that Welch’s procedure and recovery would be best managed by the congenital cardiac team at Children’s Colorado to take advantage of the hospital’s high-end imaging technologies, virtual-reality planning and the extensive experience of the entire catheterization lab team.

“Working in the medical field, I understood I needed to repair my heart, but I kept putting it off. The thought of having open-heart surgery with two babies at home wasn’t very appealing,” said Welch. “But Dr. Morgan and Dr. Kay explained how left untreated, I could go into heart failure or have a stroke. The new stent was a perfect option for me.”

Six months after surgery, Randy is feeling good, his heart looks great and his future is bright.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”